- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04722991
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat (NEON-NPDR)
A Phase 2 Randomized, Placebo-controlled, Double-masked Proof-of-concept Study to Investigate the Efficacy and Safety of Runcaciguat (BAY 1101042) in Patients With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Plovdiv, Bulgaria, 4000
- UMHAT Sveti Georgi
-
Plovdiv, Bulgaria, 4001
- Eye center Sveti Luka
-
Sofia, Bulgaria, 1309
- SEHAT Pentagram
-
Varna, Bulgaria, 9002
- Sveta Petka Eye Hospital
-
-
-
-
-
Pardubice, Czechia, 530 02
- Ocni klinika Oftex
-
Praha 10, Czechia, 100 34
- Fakultni nemocnice Kralovske Vinohrady
-
Praha 2, Czechia, 12808
- Vseobecna fakultni nemocnice v Praze
-
Praha 5, Czechia, 150 00
- AXON Clinical s.r.o.
-
-
-
-
-
Aalborg, Denmark, 9000
- Aalborg Universitetshospital, Ophtalmology dept.
-
Aarhus N, Denmark, 8200
- Aarhus Universitetshospital, Skejby
-
Glostrup, Denmark, 2600
- Glostrup Hospital
-
Odense C, Denmark, 5000
- Odense Universitetshospital, Dept of Ophtalmology
-
Roskilde, Denmark, 4000
- Sjællands Universitetshospital Roskilde
-
-
-
-
Bayern
-
Neu-Ulm, Bayern, Germany, 89231
- NUVISAN GmbH Neu-Ulm
-
-
-
-
-
Riga, Latvia, LV-1006
- Riga East Clinical University Hospital "Gailezers"
-
-
-
-
-
Amsterdam, Netherlands, 1100 DD
- Academic Medical Center Dept Ophthalmology
-
Nijmegen, Netherlands
- Universitair Medisch Centrum St. Radboud
-
Tilburg, Netherlands, 5022 GC
- ETZ Elisabeth Ziekenhuis
-
-
-
-
-
Jozefow, Poland, 05-410
- Biokinetica S.A
-
Lodz, Poland, 91-134
- Klinika Okulistyczna "Jasne Blonia" Sp. z o.o
-
Tarnowskie Gory, Poland, 42-600
- Ind. Spec. Prakt. Lek. Dr W. Jedrzejewski
-
Wroclaw, Poland, 51-162
- NZOZ Centrum Badan Klinicznych
-
-
-
-
-
Coimbra, Portugal, 3000-548
- AIBILI
-
Coimbra, Portugal, 3004-561
- CHUC - Hospitais da U. Coimbra - Servico de Oftalmologia
-
Porto, Portugal, 4200-319
- CHUSJ - Hospital Sao Joao
-
Porto, Portugal, 4099-001
- Centro Hospitalar Universitario do Porto
-
-
-
-
-
Cluj-Napoca, Romania, 400006
- Clinical Emergency County Hospital
-
-
-
-
-
Banska Bystrica, Slovakia, 97517
- Fakultna nemocnica s poliklinikou F.D.Roosevelta
-
Poprad, Slovakia, 058 45
- Nemocnica Poprad, a.s.
-
-
-
-
-
Barcelona, Spain, 08035
- Ciutat Sanitaria i Universitaria de la Vall d'Hebron
-
Sevilla, Spain, 41071
- Hospital Universitario Virgen De La Macarena
-
-
Barcelona
-
Sant Cugat del Vallés, Barcelona, Spain, 08195
- Hospital General de Catalunya
-
-
Madrid
-
Coslada, Madrid, Spain, 28822
- Hospital Universitario de Henares
-
-
-
-
-
Lausanne, Switzerland, 1004
- University Eye Hospital Jules Gonin
-
-
-
-
-
Bristol, United Kingdom, BS12LX
- Bristol Eye Hospital
-
London, United Kingdom, SE5 9RS
- King's College Hospital - NHS Foundation Trust
-
London, United Kingdom, EC1V2PD
- Moorfields Eye Hospital
-
-
Gloucestershire
-
Gloucester, Gloucestershire, United Kingdom, GL1 3NN
- Gloucester Royal Infirmary
-
-
Tyne And Wear
-
Sunderland, Tyne And Wear, United Kingdom, SR29HP
- Sunderland Eye Infirmary
-
-
-
-
California
-
Sacramento, California, United States, 95825
- Retinal Consultants Medical Group, Inc
-
-
Florida
-
Lakeland, Florida, United States, 33805-2908
- Florida Retina Consultants
-
Pinellas Park, Florida, United States, 33782
- Eye Associates of Pinellas
-
-
Maryland
-
Hagerstown, Maryland, United States, 21740
- Mid Atlantic Retina Specialists
-
Hagerstown, Maryland, United States, 21740-5940
- Cumberland Valley Retina Consultants, PC
-
-
Texas
-
Austin, Texas, United States, 78705
- Austin Retina Associates
-
Austin, Texas, United States, 78705-1023
- Austin Research Center for Retina
-
Bellaire, Texas, United States, 77401
- Retinal Consultants of Texas - San Antonio
-
McAllen, Texas, United States, 78503
- Gulf Coast Institute / Valley Retina Institute
-
San Antonio, Texas, United States, 78240
- Retinal Consultants of Texas - San Antonio
-
The Woodlands, Texas, United States, 77384
- Retina Consultants of Houston
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Moderately severe to severe NPDR in the study eye: Diabetic Retinopathy Severity Scale (DRSS) levels 47 or 53
- Diabetes type 1 or 2
- Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score in the study eye of ≥69 letters (approximate Snellen equivalent of 20/40 or better)
Main Exclusion Criteria:
- Presence or history of macular edema involving the center of the macula
- Any kind of neovascular growth in the study eye, including anterior segment neovascularization
- Arterial hypotension with systolic blood pressure < 100 or diastolic blood pressure < 60mmHg
- Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) above 3 x Upper limit of normal (ULN) or bilirubin ≥ 1.5 ULN at screening, known ascites
- Estimated glomerular filtration rate (eGFR CKD-EPI) below 30 ml/min/1.73 m^2 at screening
- Any prior systemic anti-Vascular endothelial growth factor (VEGF) treatment or IVT anti-VEGF treatment in the study eye
- Any prior intraocular steroid injection in the study eye
- Any prior grid or focal laser photocoagulation within 500 microns of the foveal center or any prior Pan-retinal photocoagulation (PRP) in the study eye
- Use of nitrates or Nitric oxide (NO) donors (such as amyl nitrate) in any form including topical; Phosphodiesterase 5 (PDE5) inhibitors, nonspecific PDE inhibitors within 1 week or less than 5 half-lives (whichever is longer) before first study drug administration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Oral dose of matching placebo
|
Experimental: Runcaciguat (BAY1101042)
|
Oral dose of runcaciguat
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
DRSS improvement ≥2 steps at 48 weeks of treatment in the study eye
Time Frame: At 48 weeks of treatment
|
DRSS (Diabetic Retinopathy Severity Scale) will be graded centrally.
|
At 48 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequency of treatment emergent adverse events
Time Frame: From first dosing up to 28 days after last dose of study intervention.
|
As reported by Investigators
|
From first dosing up to 28 days after last dose of study intervention.
|
Vision threatening complications at 48 weeks of treatment in the study eye
Time Frame: At 48 weeks
|
At 48 weeks
|
|
DRSS improvement ≥2 steps at 24 weeks of treatment in the study eye
Time Frame: At 24 weeks
|
DRSS (Diabetic Retinopathy Severity Scale) will be graded centrally.
|
At 24 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20739
- 2020-002333-15 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access.
As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.
Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Retinopathy
-
Retina Institute of HawaiiUnknownDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Severe Nonproliferative Diabetic Retinopathy | Mild Nonproliferative Diabetic Retinopathy | Moderate Nonproliferative Diabetic RetinopathyUnited States
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoCompletedProliferative Diabetic Retinopathy | Severe Nonproliferative | Active Photocoagulated Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
AEYE Health IncA. Stein Regulatory Affairs Consulting Ltd.RecruitingDiabetic Mellitus | Diabetic Retinopathy, DRUnited States
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
Clinical Trials on Runcaciguat (BAY1101042)
-
BayerTerminated
-
BayerCompletedChronic Kidney DiseaseSpain, Belgium, Austria, Germany, Bulgaria, Denmark, Italy, Israel, Sweden, Finland, Slovakia, Ukraine, Poland